---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116496"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:45:21.461027+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q3 net loss narrows to $4.0M; cash $33.1M; ATRN-119 Phase 1 initiated

## Summary
- Net loss of $4.0M ($0.12 per share) vs $9.5M ($0.45) in Q3 2021; cash and equivalents $33.1M (down from $53.1M at Dec 2021).
- R&D expenses fell to $1.1M from $6.0M due to trial close-outs and Atrin acquisition cost reductions.
- Phase 1 trial of ATR inhibitor ATRN-119 opened for enrollment; expects 1-2 additional sites in Q4 2022.
- WEE1 inhibitor ATRN-W1051 in preclinical stage; IND-enabling studies anticipated in Q4 2022.
- APR-548 Phase 1 trial closed; no ongoing clinical trials of eprenetapopt (APR-246).

## SEC filing metadata
- accession: 0001104659-22-116496
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/0001104659-22-116496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/tm2230091d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116496
- JSON: https://secwatch.observer/filing/0001104659-22-116496.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116496.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $4.0 million, or $0.12 per share, EPS $0.12 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss was $4.0 million, or $0.12 per share
  - EPS: $0.12 per share
  - Result: reported results
  source text: Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000110465922116496/0001104659-22-116496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.